Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
Type:
Grant
Filed:
November 3, 2021
Date of Patent:
December 5, 2023
Assignee:
FOG PHARMACEUTICALS, INC.
Inventors:
Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Cristina Ortet, Gregory L Verdine
Abstract: A salty taste enhancing peptide derived from dry-cured ham is provided, and the amino acid sequences thereof are Asp-Leu; Phe-Met-Ser-Ala-Leu-Phe, as shown in SEQ ID NO: 1; and His-Val-Arg-Arg-Lys, as shown in SEQ ID NO: 2. The salty taste enhancing peptide in the present disclosure is of small molecular weight, features easy separation and purification, has strong salty taste enhancing effect and simple sequences, and is easy to synthesize, therefore, the salty taste enhancing peptide can be applied to the fields of food, health products, medicine and biology, and is expected to replace salt substitute products currently available on the market.
Type:
Grant
Filed:
June 1, 2023
Date of Patent:
December 5, 2023
Assignees:
Hefei University of Technology, Yunnan Agricultural University
Inventors:
Feiran Xu, Baocai Xu, Xuefeng Wang, Zhaoming Wang, Bao Zhang, Fei Ma, Ying Wu, Kai Zhou, Hui Zhou, Kezhou Cai
Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Type:
Grant
Filed:
March 30, 2023
Date of Patent:
December 5, 2023
Assignee:
Bausch Health Ireland Limited
Inventors:
Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
Abstract: The present invention relates to a nano-ligand for promoting cell adhesion and differentiation of stem cells and a method of promoting cell adhesion and differentiation of stem cells by using the nano-ligand, and the method of promoting cell adhesion and differentiation of stem cells according to the present invention may temporally and spatially, and reversibly control nano-ligand sliding by applying a magnetic field to a substrate including the nano-ligands, and efficiently control stem cell adhesion and differentiation ex vivo or in vivo through the magnetic-field based on spatiotemporal control.
Type:
Grant
Filed:
February 26, 2021
Date of Patent:
November 28, 2023
Assignee:
Korea University Research and Business Foundation
Abstract: The present invention relates to a novel synthesis method to form particular molecules. These molecules have multiple uses, most notably in the field of protecting groups used throughout organic and synthetic chemistry. The disclosed method is safer, more cost- and time-effective, and more amenable to large scale production than those currently known in the art. The protecting groups synthesized are useful in GAP peptide synthesis.
Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
November 28, 2023
Assignees:
President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
November 28, 2023
Assignees:
Novo Nordisk Inc., United State of America, As Represented by the Secretary, Dept. of Health and Human Services
Inventors:
Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska
Abstract: Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor ??c dimer over binding the IL-2 receptor ???c trimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
November 28, 2023
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Cristina Abrahams, Edward Bowman, Xiaofan Li, Songnian Lin, Willy Solis, Ryan Stafford, Aarron Willingham, Alice Yam, Junhao Yang, Gang Yin
Abstract: The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.
Type:
Grant
Filed:
December 1, 2021
Date of Patent:
November 21, 2023
Assignee:
Cidara Therapeutics, Inc.
Inventors:
Kenneth Bartizal, Paul Daruwala, David Hughes, Martin Patrick Hughes, Navdeep B. Malkar, Balasingam Radhakrishnan, Anuradha Vaidya
Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
Type:
Grant
Filed:
May 26, 2020
Date of Patent:
November 14, 2023
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
November 7, 2023
Assignees:
Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
Abstract: Disclosed herein is an improved process for preparing abaloparatide. The process generally utilizes solid phase peptide synthesis employing an Fmoc-protection scheme. Incorporating a systematic recoupling step of a glutamine residue (Gln16) has been found to minimize the formation of an undesirable des-Gln16 abaloparatide impurity, which is often obtained in significant quantities in the conventional process.
Abstract: Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif.
Abstract: Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 3rd, 5th and 9th amino acid residues of a light chain defined by Kabat method to charged amino acid residues.
Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
October 17, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Kim Birkebaek Jensen, Magnus Bernt Fredrik Gustafsson
Abstract: In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
October 10, 2023
Assignee:
Board of Regents, the University of Texas System
Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
Abstract: A polypeptide probe for detecting G-quadruplexes (G4s), includes: from two to four G4-binding domains, and one or more linkers disposed between every two G4-binding domains. Each G4-binding domain includes a specific motif including a sequence of amino acids PGHLKGREIGMWY (SEQ ID NO: 1).